Fig. 6: Bispecific CAR T cells targeting BCMA and TACI are efficacious against wildtype multiple myeloma in vitro.
From: Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
a Luciferase-based cytotoxicity assays of MM1S, RPMI-8226, and U266 cell lines targeted by CAR T cells at the indicated E:T ratios after 18 h of coculture (n = 3ND+/– SEM in biological triplicate). Calculated as a percentage of luminescence of tumor only wells. b Cytotoxicity from a at the 1:1 E:T ratio (n = 3ND+/– SEM in biological triplicate, one way ANOVA compared to control anti-BCMA CAR). c IL-2, IFNγ, and TNFα cytokine production from supernatant of 1:1 E:T cell coculture with the indicated CAR T cells and tumor cells for 18 h (n = 3ND+/– SEM, one way ANOVA compared to control anti-BCMA CAR, ns not shown). Raw data is provided in the Source Data file. All tests are two-sided. p = ****<0.0001.
